Company: BIAF
Filing Date: 2025-09-24
Form Type: S-1
Source: 0001493152-25-014730
Chunk: 5

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-09-24
Form: S-1
Chunk 5
---
 and Pre-Funded Warrant and accompanying Common Stock Warrants will be determined between us and investors based on market conditions at the time of pricing, and may be at a discount to the then-current market price of our Common Stock. The recent market price used throughout this prospectus may not be indicative of the actual offering price. The actual public offering price may be based upon a number of factors, including our history and our prospects, the industry in which we operate, our past and present operating results, the previous experience of our executive officers, and the general condition of the securities markets at the time of this offering.

On September 17, 2025, we filed with the Secretary
of State of the State of Delaware a certificate of amendment to our certificate of incorporation to effect a one-for-thirty (1-for-30)
reverse split of our issued and outstanding shares of Common Stock. The Reverse Stock Split became effective as of 4:01 p.m. Eastern
Time on September 18, 2025, and our Common Stock began trading on a split-adjusted basis when Nasdaq opened on September 19, 2025. All
share and per share information in this prospectus (other than in the historical financial statements incorporated herein by reference)
has been adjusted to reflect the reverse stock split.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page9 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

|                                    |     | Per Share and    
 Common Stock     
 Purchase Warrant |     | Per Pre-Funded   
 Warrant and      
 Common Stock     
 Purchase Warrant |     | Total |
|:-----------------------------------|:----|:-----------------|:----|:-----------------|:----|:------|
| Public offering price              |     | $                |     | $                |     | $     |
| Placement Agent fees(1)            |     | $                |     | $                |     | $     |
| Proceeds to us, before expenses(2) |     | $                |     | $                |     | $     |

| (1) | We                                                                                                                                          
 have agreed to pay the Placement Agent a cash fee equal to 8.0% of the aggregate gross